SC&H Capital Advises CAPInnoVet on its Sale to NEOGEN

SC&H Capital served as the exclusive financial advisor to CAPInnoVet, Inc. on their sale to NEOGEN Corporation (NASDAQ: NEOG).

Founded in 2014, CAPInnoVet is an Atlanta-based companion animal health products company with the mission to provide better access to high-quality and affordable pet medications to the veterinary market. The CAPInnoVet team leverages its deep understanding of the pet medication market to capitalize on industry trends and bring novel, high-value opportunities to the market.

CAPInnoVet asked SC&H Capital to find a partner that would help to accelerate the growth of their existing companion animal health products suite and further develop their innovative pipeline of new products. SC&H Capital worked with the CAPInnoVet team to identify the right partner that would not only meet these objectives but also share similar values.

Ultimately, SC&H Capital prepared the business for sale, designed a targeted process to identify potential partners that aligned both strategically and culturally, and guided the CAPInnoVet team through the diligence process to a successful close.

CAPInnoVet was acquired by NEOGEN, a publicly-traded company that develops and markets comprehensive solutions dedicated to food and animal safety. CAPInnoVet provides NEOGEN an entry point into the fast-growing $12B+ retail parasiticide market while providing a partner to CAPInnoVet that shares its vision and values.

Read the Full Press Release

Transaction Leaders

Matthew Everett


Christopher Helmrath

Managing Director